Izervay met its primary objective of slowing geographic atrophy growth compared with sham at 24 months in the phase 3 GATHER2 clinical trial, according to a press release from Astellas Pharma.
The topline results showed that Izervay (avacincaptad pegol intravitreal solution), a complement C5 inhibitor, significantly slowed geographic atrophy (GA) growth when delivered in a monthly dosing regimen compared with sham. It also showed a similar reduction when dosed every other month.
The safety profile was consistent with previously reported 12-month data, with one case of culture-positive